ClinicalTrials.gg
CompletedNCT04770389OCEANUpdated Apr 24, 2024Results posted

Randomized Study of Obicetrapib in Combination With Ezetimibe

A Phase 2 interventional study of Obicetrapib 5mg and Ezetimibe 10mg in Dyslipidemias, High Cholesterol and Hypercholesterolemia, sponsored by NewAmsterdam Pharma. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-24.

Primary conditionHypercholesterolemiaRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NewAmsterdam Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
63rd of 97
112 · median 148
Started
2021
the only one that year
Phase 2
7 of 98
1 open now
Registered
91st of 98
by date
Lead sponsor
2 of 98
NewAmsterdam Pharma

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 63rd largest by enrollment of the 97 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 91st registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.

Read the detailed description

This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy. The screening period for this study will take up to 2 weeks. Following the screening period, eligible patients will be randomized to placebo, 5 mg obicetrapib + 10 mg ezetimibe; 5 mg obicetrapib + placebo ezetimibe; or placebo obicetrapib + 10 mg ezetimibe for an 8 week treatment period. After the treatment period, patients will continue for a 4 week safety follow-up and a 8 week PK follow-up.

03

Conditions studied

  • Dyslipidemias
  • High Cholesterol
  • Hypercholesterolemia

Browse trials for

Keywords

  • obicetrapib
  • statin
  • LDL-C
  • cholesterol
  • atherosclerosis
04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 112 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understanding of the study procedures, willingness to adhere to the study schedules and diet, and agreement to participate in the study by giving written prior to Screening procedures
  • Men or women 18 to 70 years of age, inclusive
  • Women may be enrolled if all 3 of the following criteria are met:
  • They are not pregnant;
  • They are not breastfeeding; and
  • They do not plan on becoming pregnant during the study
  • Women of must have a negative urine pregnancy test at the Screening Visit.
  • Women of childbearing potential must agree to use an effective method of avoiding pregnancy from the Screening Visit to 90 days after the last visit. Men whose partners are of childbearing potential must agree to use an effective method of avoiding pregnancy from the Screening Visit to 90 days after the last visit.
  • Fasting LDL-C levels >2.5 mmol/L (>100 mg/dL) and \<4.5 mmol/L (\<175 mg/dL) and TG levels \<4.5 mmol/L (\<400 mg/dL) (Visit 1) and
  • Willingness to maintain a stable diet and physical activity level throughout the study

Exclusion criteria

Exclusion Criteria:

  • >= 40 kg/m2
  • Participation in another clinical study involving an or marketed drug within 30 days prior to the Screening Visit
  • Currently taking any lipid-altering therapy
  • Any clinical manifestation of atherosclerotic CVD or any evidence of ischemic coronary disease present on the 12-lead at the Screening Visit
  • Diagnosis of type 1 or type 2 diabetes mellitus; or >= 6.5% at the Screening visit if no prior diagnosis of diabetes mellitus
  • Uncontrolled hypertension ie, sitting systolic blood pressure >160 mmHg and/or sitting diastolic blood pressure >90 mmHg taken as the average of triplicate measurements.

One retest will be allowed, at which point if the retest result is no longer exclusionary, the participant may be randomized

  • Active muscle disease or persistent creatine kinase concentration >3 x the (ULN). One retest will be allowed after 1 week to verify the result, at which point if the retest result is no longer exclusionary, the participant may be randomized
  • History of torsades de pointes
  • Estimated \<60 mL/min calculated using the Chronic Kidney Disease Epidemiology Collaboration equation
  • Hepatic dysfunction as evidenced by any laboratory abnormality as follows: gamma- glutamyl transferase, , or aspartate aminotransferase >2 x ULN, or total >1.5 x ULN
  • Anemia, defined as concentration \<11 g/dL for males and hemoglobin concentration \<9 g/dL for females
  • History of within the past 5 years, with the exception of non-melanoma skin cancers
  • Evidence of any other non-cardiac disease or condition that, in the opinion of the Investigator, would preclude participation in the study
  • Known ezetimibe or CETP inhibitor allergy or intolerance
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    placebo obicetrapib + placebo ezetimibe; once daily

    Other: Placebo

  • Experimental
    Combination therapy

    5 mg obicetrapib + 10 mg ezetimibe; once daily

    Drug: Obicetrapib 5mg · Drug: Ezetimibe 10mg

  • Experimental
    Obicetrapib monotherapy

    5 mg obicetrapib + placebo ezetimibe; once daily

    Drug: Obicetrapib 5mg

  • Experimental
    Ezetimibe monotherapy

    placebo obicetrapib + 10 mg ezetimibe; once daily

    Drug: Ezetimibe 10mg

Interventions

07

What researchers measure

Primary outcomes

  1. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]

    Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  2. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]

    Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  3. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]

    LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  4. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]

    Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

    Time frame: 8 weeks

  5. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]

    Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

    Time frame: 8 weeks

  6. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]

    LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

    Time frame: 8 weeks

Secondary outcomes

  1. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]

    Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  2. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]

    Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  3. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]

    LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  4. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]

    Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

    Time frame: 8 weeks

  5. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]

    Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

    Time frame: 8 weeks

  6. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]

    LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

    Time frame: 8 weeks

  7. Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo

    Mean percent change in ApoB from baseline to Day 57

    Time frame: 8 weeks

  8. Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo

    Median percent change in ApoB from baseline to Day 57

    Time frame: 8 weeks

  9. LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo

    LS Mean percent change in ApoB from baseline to Day 57

    Time frame: 8 weeks

  10. Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo

    Mean percent change in Apo-B from baseline to Day 57

    Time frame: 8 weeks

  11. Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo

    Median percent change in Apo-B from baseline to Day 57

    Time frame: 8 weeks

  12. LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo

    LS Mean percent change in Apo-B from baseline to Day 57

    Time frame: 8 weeks

  13. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]

    Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  14. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]

    Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  15. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]

    LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  16. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]

    Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  17. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]

    Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  18. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]

    LS Mean percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula

    Time frame: 8 weeks

  19. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]

    Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

    Time frame: 8 weeks

  20. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]

    Median percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula

    Time frame: 8 weeks

  21. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]

    LS Mean percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula

    Time frame: 8 weeks

  22. Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]

    Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

    Time frame: 8 weeks

  23. Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]

    Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

    Time frame: 8 weeks

  24. LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]

    LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

    Time frame: 8 weeks

  25. Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy

    Mean percent change in ApoB from baseline to Day 57

    Time frame: 8 weeks

  26. Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy

    Median percent change in ApoB from baseline to Day 57

    Time frame: 8 weeks

  27. LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy

    LS Mean Percent change in ApoB from baseline to Day 57

    Time frame: 8 weeks

08

Results

Posted Apr 24, 2024

Participant flow

234 participants were screened; out of 234, 112 participants were randomized. One participant in the ezetimibe 10 mg group was randomized in error and did not participate in the study or receive study drug

Participant flow — Overall Study
MilestonePlaceboCombination TherapyObicetrapib MonotherapyEzetimibe Monotherapy
Started28272829
Completed26222624
Not completed2525
Withdrew: Adverse event1201
Withdrew: Withdrawal by subject0210
Withdrew: Failed attempt to draw blood1000
Withdrew: Left the country0012
Withdrew: Randomized in error and did not receive study drug0001
Withdrew: Lost to follow-up0001
Withdrew: Moved away from study site0100

Outcome measures

PrimaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]

Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
percent change from baselineCombination TherapyPlacebo
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]-45.63 ± 21.677-0.17 ± 12.682
Statistical analysis
  • Combination Therapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -44.92 · 95% CI -55.20 to -34.63mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]

Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
percent change from baselineCombination TherapyPlacebo
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]-51.95 (-77.9 to 3.1)-1.40 (-20.9 to 33.6)
Statistical analysis
  • Combination Therapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -44.92 · 95% CI -55.20 to -34.63mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]

LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
percent change from baselineCombination TherapyPlacebo
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]-43.55 ± 3.7461.37 ± 3.604
Statistical analysis
  • Combination Therapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -44.92 · 95% CI -55.20 to -34.63mixed model for repeated measures (MMRM) with missing at random assumption
PrimaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]

Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]
percent change from baselineCombination TherapyPlacebo
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]-44.38 ± 20.731-1.53 ± 15.105
Statistical analysis
  • Combination Therapy vs Placebo · ANCOVA · p = <0.0001 · Least squares (ls) mean: -43.33 · 95% CI -54.29 to -32.36
PrimaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]

Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]
percent change from baselineCombination TherapyPlacebo
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]-51.40 (-69.6 to 8.1)-2.00 (-24.5 to 35.9)
Statistical analysis
  • Combination Therapy vs Placebo · ANCOVA · p = <0.0001 · Least squares (ls) mean: -43.33 · 95% CI -54.29 to -32.36
PrimaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]

LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]
percent change from baselineCombination TherapyPlacebo
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]-44.10 ± 3.813-0.78 ± 4.012
Statistical analysis
  • Combination Therapy vs Placebo · ANCOVA · p = <0.0001 · Least squares (ls) mean: -43.33 · 95% CI -54.29 to -32.36
SecondaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]

Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]
percent change from baselineObicetrapib MonotherapyPlacebo
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]-31.88 ± 18.860-0.17 ± 12.682
Statistical analysis
  • Obicetrapib Monotherapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) means: -33.36 · 95% CI -43.63 to -23.09mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]

Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]
percent change from baselineObicetrapib MonotherapyPlacebo
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]-34.40 (-57.0 to 23.8)-1.40 (-20.9 to 33.6)
Statistical analysis
  • Obicetrapib Monotherapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -33.36 · 95% CI -43.63 to -23.09mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]

LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]
percent change from baselineObicetrapib MonotherapyPlacebo
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [Friedewald]-31.99 ± 3.6861.37 ± 3.604
Statistical analysis
  • Obicetrapib Monotherapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -33.36 · 95% CI -43.63 to -23.09mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]

Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]
percent change from baselineObicetrapib MonotherapyPlacebo
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]-27.94 ± 18.914-1.53 ± 15.105
Statistical analysis
  • Obicetrapib Monotherapy vs Placebo · ANCOVA · p = <0.0001 · Least squares (ls) mean: -28.20 · 95% CI -39.32 to -17.08
SecondaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]

Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]
percent change from baselineObicetrapib MonotherapyPlacebo
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]-30.10 (-56.7 to 19.1)-2.00 (-24.5 to 35.9)
Statistical analysis
  • Obicetrapib Monotherapy vs Placebo · ANCOVA · p = <0.0001 · Least squares (ls) mean: -28.20 · 95% CI -39.32 to -17.08
SecondaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]

LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]
percent change from baselineObicetrapib MonotherapyPlacebo
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo [PUC]-28.98 ± 3.802-0.78 ± 4.012
Statistical analysis
  • Obicetrapib Monotherapy vs Placebo · ANCOVA · p = <0.0001 · Least squares (ls) mean: -28.20 · 95% CI -39.32 to -17.08
SecondaryMean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo

Mean percent change in ApoB from baseline to Day 57

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo
percent change from baselineCombination TherapyPlacebo
Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo-31.62 ± 15.521-1.17 ± 11.692
Statistical analysis
  • Combination Therapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) means: -29.62 · 95% CI -37.12 to -22.12mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo

Median percent change in ApoB from baseline to Day 57

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo
percent change from baselineCombination TherapyPlacebo
Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo-34.75 (-53.0 to 8.9)-0.90 (-19.8 to 25.4)
Statistical analysis
  • Combination Therapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -29.62 · 95% CI -37.12 to -22.12mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo

LS Mean percent change in ApoB from baseline to Day 57

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo
percent change from baselineCombination TherapyPlacebo
LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo-29.73 ± 2.730-0.11 ± 2.626
Statistical analysis
  • Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) means: -29.62 · 95% CI -37.12 to -22.12mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo

Mean percent change in Apo-B from baseline to Day 57

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo
percent change from baselineObicetrapib MonotherapyPlacebo
Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo-22.15 ± 13.356-1.17 ± 11.692
Statistical analysis
  • Obicetrapib Monotherapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -22.36 · 95% CI -29.83 to -14.88mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo

Median percent change in Apo-B from baseline to Day 57

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo
percent change from baselineObicetrapib MonotherapyPlacebo
Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo-23.50 (-39.3 to 21.2)-0.90 (-19.8 to 25.4)
Statistical analysis
  • Obicetrapib Monotherapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -22.36 · 95% CI -29.83 to -14.88mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo

LS Mean percent change in Apo-B from baseline to Day 57

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo
percent change from baselineObicetrapib MonotherapyPlacebo
LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Placebo-22.46 ± 2.675-0.11 ± 2.626
Statistical analysis
  • Obicetrapib Monotherapy vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -22.36 · 95% CI -29.83 to -14.88mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]

Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]
percent change from baselineCombination TherapyEzetimibe Monotherapy
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]-45.63 ± 21.677-12.69 ± 21.316
Statistical analysis
  • Combination Therapy vs Ezetimibe Monotherapy · Mixed Models Analysis · p = <0.0001 · Least squares (ls) means: -30.13 · 95% CI -40.55 to -19.71mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]

Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]
percent change from baselineCombination TherapyEzetimibe Monotherapy
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]-51.95 (-77.9 to 3.1)-14.80 (-51.9 to 59.1)
Statistical analysis
  • Combination Therapy vs Ezetimibe Monotherapy · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -30.13 · 95% CI -40.55 to -19.71mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]

LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]
percent change from baselineCombination TherapyEzetimibe Monotherapy
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy [Friedewald]-43.55 ± 3.746-13.42 ± 3.675
Statistical analysis
  • Combination Therapy vs Ezetimibe Monotherapy · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -30.13 · 95% CI -40.55 to -19.71mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]

Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]
percent change from baselineObicetrapib MonotherapyEzetimibe Monotherapy
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]-31.88 ± 18.860-12.69 ± 21.316
Statistical analysis
  • Obicetrapib Monotherapy vs Ezetimibe Monotherapy · Mixed Models Analysis · p = 0.0005 · Least squares (ls) means: -18.58 · 95% CI -28.88 to -8.27mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]

Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]
percent change from baselineObicetrapib MonotherapyEzetimibe Monotherapy
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]-34.40 (-57.0 to 23.8)-14.80 (-51.9 to 59.1)
Statistical analysis
  • Obicetrapib Monotherapy vs Ezetimibe Monotherapy · Mixed Models Analysis · p = 0.0005 · Least squares (ls) mean: -18.58 · 95% CI -28.88 to -8.27mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]

LS Mean percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]
percent change from baselineObicetrapib MonotherapyEzetimibe Monotherapy
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib Monotherapy Compared to Ezetimibe Monotherapy [Friedewald]-31.99 ± 3.686-13.42 ± 3.675
Statistical analysis
  • Obicetrapib Monotherapy · Mixed Models Analysis · p = 0.0005 · Least squares (ls) mean: -18.58 · 95% CI -28.88 to -8.27mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]

Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]
percent change from baselineEzetimibe MonotherapyPlacebo
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]-12.69 ± 21.316-0.17 ± 12.682
Statistical analysis
  • Ezetimibe Monotherapy vs Placebo · Mixed Models Analysis · p = 0.0051 · Least squares (ls) means: -14.79 · 95% CI -25.03 to -4.54mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]

Median percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]
percent change from baselineEzetimibe MonotherapyPlacebo
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]-14.80 (-51.9 to 59.1)-1.40 (-20.9 to 33.6)
Statistical analysis
  • Ezetimibe Monotherapy vs Placebo · Mixed Models Analysis · p = 0.0051 · Least squares (ls) mean: -14.79 · 95% CI -25.03 to -4.54mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]

LS Mean percent change in LDL-C from baseline to Day 57; LDL-C calculated using the Friedewald formula

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]
percent change from baselineEzetimibe MonotherapyPlacebo
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [Friedewald]-13.42 ± 3.6751.37 ± 3.604
Statistical analysis
  • Ezetimibe Monotherapy vs Placebo · Mixed Models Analysis · p = 0.0051 · Least squares (ls) mean: -14.79 · 95% CI -25.03 to -4.54mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]

Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]
percent change from baselineEzetimibe MonotherapyPlacebo
Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]-13.68 ± 19.573-1.53 ± 15.105
Statistical analysis
  • Ezetimibe Monotherapy vs Placebo · ANCOVA · p = 0.0245 · Least squares (ls) mean: -12.77 · 95% CI -23.86 to -1.68
SecondaryMedian Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]

Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]
percent change from baselineEzetimibe MonotherapyPlacebo
Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]-14.90 (-46.8 to 46.9)-2.00 (-24.5 to 35.9)
Statistical analysis
  • Ezetimibe Monotherapy vs Placebo · ANCOVA · p = 0.0245 · Least squares (ls) mean: -12.77 · 95% CI -23.86 to -1.68
SecondaryLS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]

LS Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC)

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]
percent change from baselineEzetimibe MonotherapyPlacebo
LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Ezetimibe Monotherapy Compared to Placebo [PUC]-13.55 ± 3.891-0.78 ± 4.012
Statistical analysis
  • Ezetimibe Monotherapy vs Placebo · ANCOVA · p = 0.0245 · Least squares (ls) mean: -12.77 · 95% CI -23.86 to -1.68
SecondaryMean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy

Mean percent change in ApoB from baseline to Day 57

Time frame:
8 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy
percent change from baselineCombination TherapyEzetimibe Monotherapy
Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy-31.62 ± 15.521-8.78 ± 14.445
Statistical analysis
  • Combination Therapy vs Ezetimibe Monotherapy · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -20.81 · 95% CI -28.39 to -13.22mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryMedian Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy

Median percent change in ApoB from baseline to Day 57

Time frame:
8 weeks
Reported as:
Median · percent change from baseline
Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy
percent change from baselineCombination TherapyEzetimibe Monotherapy
Median Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy-34.75 (-53.0 to 8.9)-8.90 (-45.4 to 32.3)
Statistical analysis
  • Combination Therapy vs Ezetimibe Monotherapy · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -20.81 · 95% CI -28.39 to -13.22mixed model for repeated measures (MMRM) with missing at random assumption
SecondaryLS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy

LS Mean Percent change in ApoB from baseline to Day 57

Time frame:
8 weeks
Reported as:
Least squares mean · percent change from baseline
LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy
percent change from baselineCombination TherapyEzetimibe Monotherapy
LS Mean Percent Change in Apolipoprotein-B (ApoB) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Ezetimibe Monotherapy-29.73 ± 2.730-8.92 ± 2.675
Statistical analysis
  • Combination Therapy vs Ezetimibe Monotherapy · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean: -20.81 · 95% CI -28.39 to -13.22mixed model for repeated measures (MMRM) with missing at random assumption

Adverse events

Collected over From first dose of study drug through Week 16. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/28 (0%)0/28 (0%)6/28 (21.4%)
Combination Therapy0/27 (0%)0/27 (0%)9/27 (33.3%)
Obicetrapib Monotherapy0/28 (0%)0/28 (0%)4/28 (14.3%)
Ezetimibe Monotherapy0/28 (0%)2/28 (7.1%)8/28 (28.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboCombination TherapyObicetrapib MonotherapyEzetimibe Monotherapy
HyperventilationRespiratory, thoracic and mediastinal disorders0/280/270/281/28
Multiple fracturesInjury, poisoning and procedural complications0/280/270/281/28
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlaceboCombination TherapyObicetrapib MonotherapyEzetimibe Monotherapy
DiarrhoeaGastrointestinal disorders0/282/270/282/28
HeadacheNervous system disorders1/281/270/282/28
Abdominal painGastrointestinal disorders0/281/270/280/28
Upper respiratory tract infectionInfections and infestations0/281/271/280/28
InfluenzaInfections and infestations0/281/270/280/28
DizzinessNervous system disorders0/281/270/280/28
Back painMusculoskeletal and connective tissue disorders0/281/270/280/28
SARS-CoV-2 test positiveInvestigations0/281/270/280/28
Decreased appetiteMetabolism and nutrition disorders0/281/270/280/28
HypertensionVascular disorders0/281/270/280/28

Baseline characteristics

The study was revised from a 12-week treatment period to an 8-week treatment period in response to the global COVID-19 pandemic. Baseline Population is defined as all participants who received at least one dose of study drug and had a baseline value for LDL-C assessment.

Age, Continuous
Age, Continuous(years)PlaceboCombination TherapyObicetrapib MonotherapyEzetimibe MonotherapyTotal
Mean54.5 ± 9.8153.5 ± 11.4359.1 ± 7.5054.4 ± 9.5555.4 ± 9.78
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCombination TherapyObicetrapib MonotherapyEzetimibe MonotherapyTotal
Female1616141460
Male1211141451
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCombination TherapyObicetrapib MonotherapyEzetimibe MonotherapyTotal
Hispanic or Latino00011
Not Hispanic or Latino26262725104
Unknown or Not Reported21126
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCombination TherapyObicetrapib MonotherapyEzetimibe MonotherapyTotal
American Indian or Alaska Native00000
Asian354416
Native Hawaiian or Other Pacific Islander00000
Black or African American10102
White2422232493
More than one race00000
Unknown or Not Reported00000
Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values
Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Values(milligrams per deciliter (mg/dL))PlaceboCombination TherapyObicetrapib MonotherapyEzetimibe MonotherapyTotal
Mean136.8 ± 19.86132.2 ± 27.48127.5 ± 20.87128.0 ± 22.33131.13 ± 22.64
09

Study locations

9 sites
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Evanston Premier Healthcare Research LLC
    Evanston, Illinois 60201, United States
  • Juno Research, LLC - Medical Center Office
    Houston, Texas 77054, United States
  • Medisch Centrum Thomsonplein
    Den Haag, 2565 KN, Netherlands
  • Huisartsen Praktijk Rambharose
    Den Haag, 2572 GM, Netherlands
  • Huisartsen Praktijk A.M.N. Zijtregto
    Rotterdam, 3037 AN, Netherlands
  • Huisartsen Praktijk van Soerland
    Rotterdam, 3067 GJ, Netherlands
  • Huisartsen Praktijk Broekman
    Zwijndrecht, 3333 GZ, Netherlands
  • Dokters van Nederhoven
    Zwijndrecht, 3334 SB, Netherlands
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2021, 2 months.

Results were first posted in Apr 2024, 2 years 11 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 2 months is below that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2021
First posted
Feb 25, 2021
StartActual
Feb 23, 2021
Primary completionActual
May 7, 2021
CompletionActual
Jun 30, 2021
Results first posted
Apr 24, 2024
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04770389
Lead sponsor
NewAmsterdam Pharma
Responsible party
Sponsor
First posted
Feb 25, 2021
Start date
Feb 23, 2021
Primary completion
May 7, 2021
Completion
Jun 30, 2021
Results posted
Apr 24, 2024
Last update
Apr 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: TA-8995 · Ezetimibe

Start the discussion